RGNXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
REGENXBIO Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$7.15+0.23 (+3.25%)
Close on Oct 19, 2026
- Market cap
- $379.06M
- P/E (TTM)
- –
- Dividend yield
- –
Regenxbio statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Regenxbio | Industry median |
|---|---|---|
| Market Cap | $471.99M | $197.05M |
| Enterprise Value | $366.49M | $106.56M |
| PS Ratio | 2.71 | 3.93 |
| PB Ratio | 6.58 | 2.14 |
| P/TBV Ratio | 6.58 | 2.46 |
Enterprise value
| Measure | Regenxbio | Industry median |
|---|---|---|
| EV / Sales | 2.10 | 2.69 |
Income (trailing twelve months)
| Measure | Regenxbio | Industry median |
|---|---|---|
| Revenue | $174.48M | $57.94M |
| Operating Income | -$164.15M | -$21.44M |
| Net Income | -$196.43M | -$22.46M |
| EBITDA | -$148.78M | -$16.91M |
| EPS (Diluted) | -$3.79 | -$0.83 |
Margins
| Measure | Regenxbio | Industry median |
|---|---|---|
| Operating Margin | -94.1% | -44.5% |
| Profit Margin | -112.6% | -39.2% |
| EBITDA Margin | -85.3% | -31.3% |
| FCF Margin | -143.1% | -8.85% |
Returns
| Measure | Regenxbio | Industry median |
|---|---|---|
| Return on Equity (ROE) | -137.6% | -53.1% |
| Return on Assets (ROA) | -40.6% | -41.0% |
| Return on Capital Employed (ROCE) | -54.0% | -37.8% |
Growth
| Measure | Regenxbio | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 12.0% | 6.01% |
| Revenue Growth (3Y CAGR) | 14.8% | 2.25% |
| Revenue Growth (5Y CAGR) | 1.97% | 6.42% |
Balance sheet
| Measure | Regenxbio | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $105.50M | $62.42M |
| Net Cash (Debt) | $105.50M | $15.68M |
| Net Cash Per Share | $1.60 | $0.65 |
| Equity (Book Value) | $71.77M | $48.79M |
| Book Value Per Share | $1.09 | $1.36 |
| Tangible Book Value | $71.77M | $23.06M |
| Working Capital | $153.54M | $75.77M |
Financial position
| Measure | Regenxbio | Industry median |
|---|---|---|
| Current Ratio | 2.86 | 3.30 |
| Quick Ratio | 2.57 | 2.39 |
| Interest Coverage | -3.91 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Regenxbio | Industry median |
|---|---|---|
| Operating Cash Flow | -$246.67M | -$12.35M |
| Capital Expenditures | -$2.99M | -$1.06M |
| Free Cash Flow | -$249.67M | -$20.28M |
| FCF Per Share | -$3.78 | -$0.41 |
Efficiency
| Measure | Regenxbio | Industry median |
|---|---|---|
| Asset Turnover | 0.36 | 0.38 |
| Revenue Per Employee | $470.30K | $398.96K |
| Profits Per Employee | -$529.47K | -$732.08K |
| Employee Count | 371 | 73 |
Dividends and yields
| Measure | Regenxbio | Industry median |
|---|---|---|
| Earnings Yield | -41.6% | -21.2% |
| FCF Yield | -52.9% | -7.64% |
Shares
| Measure | Regenxbio | Industry median |
|---|---|---|
| Shares Outstanding | 66,013,200 | 59,128,900 |
| Shares Change (YoY) | 2.09% | 11.1% |
| Shares Change (QoQ) | 4.93% | 0.54% |
| Float | 61,102,200 | 48,744,500 |
| Shares Held by Insiders | 7.44% | 11.8% |
| Shares Held by Institutions | 64.2% | 59.4% |
Scores
| Measure | Regenxbio | Industry median |
|---|---|---|
| Altman Z-Score | -3.90 | 0.10 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Regenxbio's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.